Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Fusion Pharmaceuticals

11/05/2023 14:27

* Fusion Pharmaceuticals Inc  FUSN.OQ  reported a quarterly
adjusted loss of 45 cents​​ per share for the quarter ended in
March. The mean expectation of eight analysts for the quarter
was for a loss of 32 cents per share.
    * Revenue fell 95.2% to $28.00 thousand from a year ago;
analysts
expected $8.57 million. 
    * Fusion Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 45 cents​.
    * The mean earnings estimate of analysts had risen by
about 37.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Fusion Pharmaceuticals Inc shares had risen by 18.6% this
quarter and gained 41.9% so far this year.
    * The company reported a quarterly loss of $24.29 million.
    * Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 11 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 01:27 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.32          -0.45          Missed
 Dec. 31 2022      -0.56          -0.55          Beat
 Sep. 30 2022      -0.50          -0.55          Missed
 Jun. 30 2022      -0.53          -0.44          Beat